SG11201700331RA - Prophylactic or therapeutic agent for a posterior ocular disease - Google Patents

Prophylactic or therapeutic agent for a posterior ocular disease

Info

Publication number
SG11201700331RA
SG11201700331RA SG11201700331RA SG11201700331RA SG11201700331RA SG 11201700331R A SG11201700331R A SG 11201700331RA SG 11201700331R A SG11201700331R A SG 11201700331RA SG 11201700331R A SG11201700331R A SG 11201700331RA SG 11201700331R A SG11201700331R A SG 11201700331RA
Authority
SG
Singapore
Prior art keywords
prophylactic
therapeutic agent
ocular disease
posterior ocular
posterior
Prior art date
Application number
SG11201700331RA
Other languages
English (en)
Inventor
Atsushi Yoshida
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of SG11201700331RA publication Critical patent/SG11201700331RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201700331RA 2014-07-17 2015-07-17 Prophylactic or therapeutic agent for a posterior ocular disease SG11201700331RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014146573 2014-07-17
PCT/JP2015/070477 WO2016010130A1 (fr) 2014-07-17 2015-07-17 Agent prophylactique ou thérapeutique pour des troubles du segment postérieur de l'œil

Publications (1)

Publication Number Publication Date
SG11201700331RA true SG11201700331RA (en) 2017-02-27

Family

ID=55078616

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201700331RA SG11201700331RA (en) 2014-07-17 2015-07-17 Prophylactic or therapeutic agent for a posterior ocular disease

Country Status (14)

Country Link
US (1) US20170202845A1 (fr)
EP (1) EP3170500A4 (fr)
JP (1) JP2016029037A (fr)
KR (1) KR20170029513A (fr)
CN (1) CN106456641A (fr)
BR (1) BR112017000991A2 (fr)
CA (1) CA2955862A1 (fr)
EA (1) EA201790231A1 (fr)
MA (1) MA40320A (fr)
MX (1) MX2017000580A (fr)
PH (1) PH12017500106A1 (fr)
SG (1) SG11201700331RA (fr)
TW (1) TW201625255A (fr)
WO (1) WO2016010130A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687508B2 (en) * 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7629351B2 (en) * 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
US8383812B2 (en) * 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
BR112013015234B1 (pt) * 2010-12-16 2020-04-22 Allergan Inc composto e composição farmacêutica
AU2012206945B2 (en) * 2011-01-11 2015-02-19 Dimerix Bioscience Pty Ltd Combination therapy
WO2014133072A1 (fr) * 2013-02-28 2014-09-04 参天製薬株式会社 Agent de prévention ou de traitement de maladies de la partie postérieure de l'œil contenant un dérivé de tétrahydropyranylaminocyclopentylcarbonyltétrahydropyridopyridine en tant que principe actif

Also Published As

Publication number Publication date
PH12017500106A1 (en) 2017-05-22
TW201625255A (zh) 2016-07-16
MX2017000580A (es) 2017-09-01
EA201790231A1 (ru) 2017-05-31
CN106456641A (zh) 2017-02-22
US20170202845A1 (en) 2017-07-20
BR112017000991A2 (pt) 2018-07-24
EP3170500A1 (fr) 2017-05-24
MA40320A (fr) 2017-05-24
KR20170029513A (ko) 2017-03-15
CA2955862A1 (fr) 2016-01-21
JP2016029037A (ja) 2016-03-03
EP3170500A4 (fr) 2018-03-14
WO2016010130A1 (fr) 2016-01-21

Similar Documents

Publication Publication Date Title
IL283561B (en) Methods for treating eye diseases
ZA201608108B (en) Huntington's disease therapeutic compounds
IL275306A (en) Instruments for eye surgery
GB2531994B (en) Surgical articulation
GB201913962D0 (en) Ophthalmic drug compositions
PL3722274T3 (pl) Związki semifluorowane
EP3166551A4 (fr) Pièce à main chirurgicale pour une opération de la cataracte
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
EP3209331C0 (fr) Solution ophtalmique
IL250990A0 (en) Materials for human care
HK1245066A1 (zh) 眼科手術裝置
GB201505032D0 (en) Orthotic insole
GB2523603B (en) Knee prosthesis
SI3148492T1 (sl) Laserska terapevtska naprava za oftalmologijo
GB201815035D0 (en) Ophthalmic drug compositions
EP3061455A4 (fr) Agent thérapeutique pour maladie oculaire ou agent prophylactique pour maladie oculaire
EP3380049C0 (fr) Prothèse pour patients porteurs d'entérostomie
RS61504B1 (sr) Jedinjenja heteroarila za lečenje oftalmičkih bolesti
EP3474836C0 (fr) Médicament ophtalmique contenant du salbutamol.
GB201502647D0 (en) Medical implant
IL259381B (en) Miravegron for the treatment of retinal diseases
EP2950782A4 (fr) Préparations à libération prolongée pour le traitement de la pression intra-oculaire élevée ou glaucome
SG11201700331RA (en) Prophylactic or therapeutic agent for a posterior ocular disease
EP3189847A4 (fr) Agent thérapeutique ou prophylactique contre des maladies de la peau provoquant des démangeaisons
PL2893906T3 (pl) Endoproteza kolana z tylną stabilizacją